Fig. 2: Abnormal glycosylation of B7H3 at N91/N309 and N104/N322 sites blocks its ER-to-Golgi translocation.
From: Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity
a Confocal microscopy of MDA-MB-231-B7H3KO and A549-B7H3KO cells reconstituted with human B7H3-WT and B7H3-NQ mutant cDNA. Green, Actin; Red, B7H3. Scar bar, 50 µm. b Confocal microscopy of MDA-MB-231-B7H3KO and A549-B7H3KO cells co-expressed with human mNegoGreen-B7H3-WT cDNA or mNegoGreen-B7H3-NQ mutant cDNA, and KDEL-mRuby cDNA. BF, bright field; Green, B7H3; Red, ER marker (KDEL). Scale bars, 20 μm. c Immuno- fluorescence staining with antibodies against B7H3(red) and ERGIC (green). Scale bars,100 μm. d Immunofluorescence staining with antibodies against B7H3 (red) and TGN38 (green) in the indicated cell lines. Scale bars,100μm. DAPI and Hoechst: nuclear counterstaining. Data are representative of three independent experiments.
